• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腋窝清扫术时检出的淋巴结数量:新辅助化疗及其他因素的影响。

Number of lymph nodes identified at axillary dissection: effect of neoadjuvant chemotherapy and other factors.

机构信息

Department of Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

出版信息

Cancer. 2010 Jul 15;116(14):3322-9. doi: 10.1002/cncr.25207.

DOI:10.1002/cncr.25207
PMID:20564124
Abstract

BACKGROUND

Several reports have shown a significantly lower number of axillary lymph nodes (AxLNs) found at axillary lymph node dissection (ALND) after neoadjuvant chemotherapy. The objective of the current study was to investigate the factors affecting the number of AxLNs identified at ALND.

METHODS

Medical records of patients seen at the study institution, a tertiary center, from 2004 to 2007 who underwent ALND for breast cancer were reviewed.

RESULTS

Among the 698 patients who met study criteria, the mean number of AxLNs resected was 20.4. There were 649 (93%) patients with at least 10 AxLNs recovered. Seventy-one (10%) patients received neoadjuvant chemotherapy and 627 (90%) underwent surgical resection first. The mean number of AxLNs in the patients treated with neoadjuvant chemotherapy was 21.9 (range, 4-56 AxLNs) compared with 20.2 (range, 5-65 AxLNs) in the group treated with surgical resection first (P=.13). The number of patients with <10 AxLNs found at ALND was 44 of 627 (7.0%) in the surgical resection first group and 5 of 71 (7.0%) in the neoadjuvant chemotherapy group (P=1.0). The mean number of AxLNs was higher in the 599 (86%) ALNDs performed at the study center compared with the 99 cases from outside institutions (21.2 vs 15.2 AxLNs; P<.001). Among the cases performed at the study institution, 367 (61%) were performed by surgeons with oncologic training and 232 (39%) were not. Surgical oncologists recovered an average of 23 AxLNs, which was significantly higher than the 18.4 resected by the remaining surgeons (P<.001).

CONCLUSIONS

The number of AxLNs recovered at ALND does not appear to be affected by neoadjuvant chemotherapy. Surgeons with oncologic training appear to retrieve more AxLNs.

摘要

背景

多项研究显示,新辅助化疗后腋窝淋巴结清扫术(ALND)中检出的腋窝淋巴结(AxLNs)数量明显减少。本研究旨在探讨影响 ALND 中 AxLNs 检出数量的因素。

方法

回顾 2004 年至 2007 年在研究机构(三级中心)接受 ALND 治疗的乳腺癌患者的病历资料。

结果

在符合研究标准的 698 例患者中,切除的 AxLNs 平均数量为 20.4 个。有 649(93%)例患者至少回收了 10 个 AxLNs。71(10%)例患者接受新辅助化疗,627(90%)例患者先进行手术切除。接受新辅助化疗的患者的 AxLNs 平均数量为 21.9(范围 4-56 个),而先进行手术切除的患者为 20.2(范围 5-65 个)(P=.13)。先手术切除组中,ALND 发现<10 个 AxLNs 的患者有 44 例(7.0%),新辅助化疗组为 5 例(7.0%)(P=1.0)。研究中心进行的 599 例(86%)ALND 的 AxLNs 数量高于外院的 99 例(21.2 与 15.2 个;P<.001)。在研究机构进行的病例中,367 例(61%)由具有肿瘤学培训的外科医生进行,232 例(39%)不由具有肿瘤学培训的外科医生进行。肿瘤外科医生平均切除 23 个 AxLNs,明显高于其余外科医生的 18.4 个(P<.001)。

结论

ALND 中回收的 AxLNs 数量似乎不受新辅助化疗的影响。具有肿瘤学培训的外科医生似乎可以取出更多的 AxLNs。

相似文献

1
Number of lymph nodes identified at axillary dissection: effect of neoadjuvant chemotherapy and other factors.腋窝清扫术时检出的淋巴结数量:新辅助化疗及其他因素的影响。
Cancer. 2010 Jul 15;116(14):3322-9. doi: 10.1002/cncr.25207.
2
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.新辅助化疗治疗的Ⅱ/Ⅲ期乳腺癌腋窝淋巴结比率的临床意义
Breast Cancer Res Treat. 2009 Jul;116(1):153-60. doi: 10.1007/s10549-008-0160-9. Epub 2008 Sep 12.
3
Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count.浸润性乳腺癌的新辅助化疗可使腋窝淋巴结计数降低。
J Am Coll Surg. 2008 Apr;206(4):704-8. doi: 10.1016/j.jamcollsurg.2007.10.016.
4
Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.新辅助化疗后乳腺癌患者的前哨淋巴结活检
J Surg Oncol. 2003 Oct;84(2):63-7. doi: 10.1002/jso.10294.
5
Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.新辅助化疗的临床和病理反应与局部晚期乳腺癌预后的关系
J Surg Oncol. 2002 May;80(1):4-11. doi: 10.1002/jso.10090.
6
Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.新辅助化疗后乳腺癌腋窝前哨淋巴结活检。
Cancer. 2010 Mar 1;116(5):1243-51. doi: 10.1002/cncr.24887.
7
Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer.早期乳腺癌患者腋窝淋巴结清扫范围与患者、肿瘤、外科医生及医院因素之间的关联
J Surg Oncol. 2003 Feb;82(2):84-90. doi: 10.1002/jso.10198.
8
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.新辅助化疗后乳腺的病理肿瘤反应可预测腋窝淋巴结状态。
Cancer J Sci Am. 1998 Jul-Aug;4(4):230-6.
9
Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.早期乳腺癌患者前哨淋巴结活检与腋窝淋巴结清扫术后的长期发病率比较
J Surg Oncol. 2006 Feb 1;93(2):109-19. doi: 10.1002/jso.20406.
10
Axillary staging prior to or after neoadjuvant systemic therapy? A single institutional experience.新辅助全身治疗前后行腋窝分期?单中心经验。
J Surg Oncol. 2010 Oct 1;102(5):404-7. doi: 10.1002/jso.21466.

引用本文的文献

1
The yield of axillary clearance in breast cancer in Khartoum locality -Sudan: a cross-sectional study.苏丹喀土穆地区乳腺癌腋窝清扫术的产量:一项横断面研究。
Ann Med Surg (Lond). 2025 Mar 18;87(5):2589-2601. doi: 10.1097/MS9.0000000000003187. eCollection 2025 May.
2
Temporal Trends and Factors Associated with Receipt of Post-mastectomy Radiation After Neoadjuvant Chemotherapy in Women with cT3 Breast Cancer.新辅助化疗后 cT3 期乳腺癌患者接受乳房切除术放疗的时间趋势和相关因素。
Ann Surg Oncol. 2023 Oct;30(11):6506-6515. doi: 10.1245/s10434-023-13730-x. Epub 2023 Jul 17.
3
Impacts of neoadjuvant therapy on the number of dissected lymph nodes in esophagogastric junction cancer patients.
新辅助治疗对食管胃结合部癌患者淋巴结清扫数量的影响。
BMC Gastroenterol. 2023 Mar 9;23(1):64. doi: 10.1186/s12876-023-02705-7.
4
Higher Pathological Complete Response Rate of Less than 10 Total Axillary Lymph Nodes After Axillary Lymph Node Dissection Following Neoadjuvant Chemotherapy in Breast Cancer.乳腺癌新辅助化疗后腋窝淋巴结清扫术治疗腋窝淋巴结总数少于10个时更高的病理完全缓解率
Front Surg. 2022 Mar 31;9:678169. doi: 10.3389/fsurg.2022.678169. eCollection 2022.
5
A new era of neoadjuvant treatment with Pertuzumab: Should the 10-lymph node guideline for axillary lymph node dissection in breast cancer be revised?帕妥珠单抗新辅助治疗时代:乳腺癌腋窝淋巴结清扫术 10 淋巴结清扫指南是否需要修改?
Cancer Rep (Hoboken). 2018 Dec;1(4):e1132. doi: 10.1002/cnr2.1132. Epub 2018 Sep 16.
6
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.乳腺癌新辅助治疗后标本临床研究中病理评估和报告的标准化:国际工作组的建议。
Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24.
7
Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.新辅助化疗后乳腺癌预后评估中残余癌负担的可重复性
Mod Pathol. 2015 Jul;28(7):913-20. doi: 10.1038/modpathol.2015.53. Epub 2015 May 1.
8
Is elective nodal irradiation beneficial in patients with pathologically negative lymph nodes after neoadjuvant chemotherapy and breast-conserving surgery for clinical stage II-III breast cancer? A multicentre retrospective study (KROG 12-05).新辅助化疗和保乳手术后病理阴性淋巴结的临床 II-III 期乳腺癌患者选择性淋巴结照射是否有益?一项多中心回顾性研究(KROG 12-05)。
Br J Cancer. 2014 Mar 18;110(6):1420-6. doi: 10.1038/bjc.2014.26. Epub 2014 Jan 30.
9
Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer.新辅助化疗后腋窝淋巴结状态(经病理完全缓解调整)预测乳腺癌的无病生存差异。
Curr Oncol. 2013 Jun;20(3):e180-92. doi: 10.3747/co.20.1294.
10
Does the axillary lymph node ratio have any added prognostic value over pN staging for South East Asian breast cancer patients?腋窝淋巴结比率对东南亚乳腺癌患者的 pN 分期有附加预后价值吗?
PLoS One. 2012;7(9):e45809. doi: 10.1371/journal.pone.0045809. Epub 2012 Sep 24.